345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

医学 湿疹面积及严重程度指数 安慰剂 斯科拉德 临床终点 内科学 随机对照试验 特应性皮炎 胃肠病学 免疫学 疾病 病理 皮肤科生活质量指数 替代医学
作者
Stephan Weidinger,Michael J. Cork,Adam Reich,Thomas Bieber,Sally Gilbert,Nuala Brennan,Rosamund Wilson,Davide Lucchesi,Natalie Rynkiewicz,Marisa Stebegg,Ben Porter‐Brown
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:188 (Supplement_2) 被引量:8
标识
DOI:10.1093/bjd/ljac140.039
摘要

Abstract OX40Ligand (OX40L) upregulation on antigen-presenting cells (APCs) following antigen presentation contributes to the survival and functional activation of T helper (Th) 2 and Th1/17/22 cells, which are central to the inflammation and pathological outcomes in atopic dermatitis (AD). In a Phase 2a trial (NCT03754309), amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40L monoclonal antibody, was effective in treating patients with moderate-to-severe AD. To assess the effects of amlitelimab on interleukin (IL)-22, an important Th22-associated disease mediator of AD. 89 patients with moderate-to-severe AD were enrolled in a Phase 2a randomized, double-blind, placebo-controlled, multicentre trial and randomized 1 : 1 : 1 to intravenous amlitelimab low dose (200 mg loading/100 mg maintenance every 4 weeks [Q4W]; n = 29), high dose (500 mg/250 mg Q4W; n = 30) or placebo (Q4W; n = 29) until week 12. The primary efficacy endpoint was the percentage change in Eczema Area and Severity Index (EASI) from baseline to week 16. Other disease severity measurements included SCORing of Atopic Dermatitis (SCORAD) and validated Investigator Global Assessment (vIGA). Serum was collected at baseline, week 4 and week 16, and further collected at week 24 and week 36 in responders, defined as patients who reached vIGA 0/1 at week 16. IL-22 levels were determined by ultrasensitive single-molecule immunoassay (Simoa). Of 88 subjects who received study treatment, 59 were evaluable at week 16. Amlitelimab was well tolerated with an unremarkable safety profile. The mean percentage change in EASI from baseline at week 16 was −80.12% for amlitelimab low dose and −69.97% for amlitelimab high dose vs. −49.37% for placebo (nominal P-values: 0.009 [amlitelimab low dose vs. placebo] and 0.072 [amlitelimab high dose vs. placebo]). Amlitelimab-treated patients who achieved vIGA 0/1 at week 16 had sustained clinical responses up to week 36. No difference in IL-22 serum levels was found between groups at baseline. IL-22 levels correlated with disease severity at baseline, as measured by EASI and SCORAD (r = 0.53, P < 0.0001; and r = 0.36, P = 0.001; respectively). A significant reduction in IL-22 levels was observed at week 16 in amlitelimab-treated patients (low dose P < 0.0001; high dose P = 0.001), but not in the placebo group (P = 0.381). The amlitelimab-induced decrease in IL-22 levels was maintained until week 36 in those defined as vIGA 0/1 responders at week 16. OX40L blockade on APCs represents a promising novel approach in the treatment of AD by effectively targeting underlying T-cell immune dysregulation. Amlitelimab monotherapy not only provided a sustained and clinically meaningful improvement in disease activity compared with placebo in patients with moderate-to-severe AD, but also significantly decreased serum levels of IL-22, a Th22 cell-associated cytokine involved in the underlying immunopathogenesis of AD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Raul发布了新的文献求助10
4秒前
5秒前
明明完成签到,获得积分10
5秒前
Yukangqian完成签到,获得积分20
5秒前
王饼干完成签到,获得积分10
6秒前
噗噗发布了新的文献求助10
8秒前
追三发布了新的文献求助10
8秒前
9秒前
li完成签到,获得积分10
10秒前
11秒前
Raul完成签到,获得积分20
11秒前
11秒前
12秒前
小马甲应助xn201120采纳,获得150
14秒前
14秒前
pearer完成签到,获得积分10
15秒前
15秒前
Akim应助li采纳,获得10
15秒前
小冉完成签到,获得积分10
16秒前
李健的小迷弟应助蒋紫妍采纳,获得10
16秒前
17秒前
Later发布了新的文献求助10
17秒前
John完成签到,获得积分10
17秒前
18秒前
Yukangqian发布了新的文献求助10
19秒前
纸鸢发布了新的文献求助10
20秒前
21秒前
Wang0102完成签到,获得积分10
22秒前
SciGPT应助CyS采纳,获得10
22秒前
丘比特应助徐徐采纳,获得10
23秒前
23秒前
丽Li完成签到,获得积分10
23秒前
纸鸢完成签到,获得积分10
23秒前
FashionBoy应助mtw采纳,获得10
27秒前
苗苗发布了新的文献求助10
27秒前
爆米花应助何敏娟采纳,获得10
28秒前
29秒前
29秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976235
求助须知:如何正确求助?哪些是违规求助? 3520399
关于积分的说明 11203166
捐赠科研通 3256989
什么是DOI,文献DOI怎么找? 1798580
邀请新用户注册赠送积分活动 877738
科研通“疑难数据库(出版商)”最低求助积分说明 806516